Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediPharm LabsSTU:MLZ -1.09% PS Ratio is 0.75 as of Aug. 28, 2026, which is 19% below its 10-year median of 0.93. The stock has 4 warning signs investors should review. Among 951 Drug Manufacturers companies, MediPharm Labs ranks better than 78.86% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, MediPharm Labs's share price is €0.0455.
MediPharm Labs's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €0.06. Hence, MediPharm Labs's PS Ratio for today is 0.75.
Warning Sign:
MediPharm Labs Corp stock PS Ratio (=0.82) is close to 1-year high of 0.88.
The historical rank and industry rank for MediPharm Labs's PS Ratio or its related term are showing as below:
STU:MLZ'
s PS Ratio Range Over the Past 10 Years
Min: 0.59 Med: 0.93 Max: 33.85
Current: 0.82
During the past 9 years, MediPharm Labs's highest PS Ratio was 33.85. The lowest was 0.59. And the median was 0.93.
STU:MLZ's PS Ratio is ranked better than 78.86% of 951
companies
in the Drug Manufacturers industry
Industry Median: 2.38
vs STU:MLZ: 0.82
MediPharm Labs Corp revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of MediPharm Labs was -9.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 10.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -10.20% per year.
During the past 9 years, MediPharm Labs's highest 3-Year average Revenue per Share Growth Rate was 10.50% per year. The lowest was -56.30% per year. And the median was -11.85% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
MediPharm Labs PS Ratio Related Terms
MediPharm Labs PS Ratio Historical Data
* Premium members only.
The historical data trend for MediPharm Labs's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediPharm Labs PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's PS Ratio distribution charts can be found below:
* The bar in red indicates where MediPharm Labs's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
MediPharm Labs's Share Price of today is €0.0455. MediPharm Labs's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
MediPharm Labs (STU:MLZ) has a PS Ratio of 0.75 as of Aug. 28, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on MediPharm Labs and its competitors. This is 19% below median its historical median of 0.93. Over the past decade, MediPharm Labs' PS Ratio has ranged from 0.59 to 33.85. According to the industry distribution chart, MediPharm Labs ranks #201 out of 951 companies in the Drug Manufacturers industry, placing it in the top 21.1%.
Is MediPharm Labs' PS Ratio too high?
MediPharm Labs' current PS Ratio of 0.75 is 19% below median its 10-year median of 0.93. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 33.85. The Drug Manufacturers industry median PS Ratio is 2.38. MediPharm Labs' value of 0.75 is 68.5% below this industry median. Based on the distribution chart, MediPharm Labs ranks #201 out of 951 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does MediPharm Labs' PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, MediPharm Labs ranks #201 out of 951 companies for PS Ratio. This places MediPharm Labs in the top 21% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.38. MediPharm Labs' value of 0.75 is 68.5% below this benchmark. Historically, MediPharm Labs' own PS Ratio has ranged from 0.59 to 33.85 over the past decade. While the company's 10-year median is 0.93 vs. the industry median of 2.38, MediPharm Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.38, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediPharm Labs's current PS Ratio of 0.75 is 68.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on MediPharm Labs and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediPharm Labs's current PS Ratio is 0.75, which is 19% below median its own 10-year median of 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediPharm Labs stock overvalued right now?
Based on GuruFocus' analysis, MediPharm Labs (STU:MLZ) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.05 — trading 13.8% above its estimated fair value. The current PS Ratio is 0.75, which is 19% below median its 10-year median of 0.93 and 68.5% below the Drug Manufacturers industry median of 2.38. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For MediPharm Labs (STU:MLZ), the current PS Ratio is 0.75 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MLZ has been successfully added to your 
